Molecular Partners AG Namens-Aktien SF 1

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

11.33%

Market Cap

124.54 Mil.

P/E Ratio

0.00

Dividend Yield

0.00 %

Earnings per Share

-1.77 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE3.32 G0 Units
PRICE DETERMINATION TIME06/23/2026 / 09:57:12 PM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW3.383.28
PREV. DAY'S PRICE3.34 (06/22)
CHANGE DAY BEFORE
-0.02
-0.60 %
52 WEEK HIGH / LOW4.365 (03/06)2.87 (10/21)
More Price Information

Key Figures (in EUR)

2027e2026e202520242023
EARNINGS PER SHARE-1.46-1.50-1.77-1.67-1.95
DIVIDENDS PER SHARE0.000.000.000.000.00
DIVIDEND YIELD IN %--0.00 %0.00 %0.00 %
DIVIDEND GROWTH IN %-----
PRICE - EARNINGS RATIO-----
PRICE - BOOK RATIO--1.581.060.64
PRICE - SALES RATIO---27.8016.02
PRICE - CASH FLOW RATIO-----
Further Key Figures

Master Data

WKN
A12DEH
ISIN
CH0256379097
SYMBOL
6ML
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
MOLECULAR PARTNERS SF 1
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
Swiss Franc
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
37.51 Mil.
MARKET CAPITALISATION
124.54 Mil.

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
1.83 %
-1.18 %
-10.46 %
-9.12 %
11.33 %
--
-5.52 %
HIGH3.443.503.784.374.37--4.37
LOW3.263.223.063.062.87--3.06
Dividend
per share
MOLECULAR PARTNERS SF 1 does not deliver dividend information

Company profile

Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.